Lyophilized compositions comprosing albumin-EGFR paclitaxel nanoparticle complexes
Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
1. A lyophilized composition comprising nanoparticle complexes comprising:
albumin;
antibodies, each having an epidermal growth factor receptor (EGFR)-binding portion; and
paclitaxel;
said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution the nanoparticle complexes—have binding specificity for EGFR expressed by a cancer cell in vivo, wherein said complexes have an average size of less than 1 μm, and wherein the antibodies are associated with the albumin through non-covalent bonds.
2. The lyophilized composition of claim 1 that is stable at about 20° C. to about 25° C. for at least 3 months.
3. The lyophilized composition of claim 1 , wherein each of the nanoparticle complexes comprises between about 400 and about 800 antibodies.
4. The lyophilized composition of claim 1 , wherein the albumin is human serum albumin.
5. The lyophilized composition of claim 1 , wherein the nanoparticle complexes have a dissociation constant between about 1×10 −11 M and about 1×10 −9 M.
6. The lyophilized composition of claim 1 which does not contain a bulking agent.
7. The lyophilized composition of claim 1 , wherein less than 0.01% of nanoparticle complexes have a size greater than 800 nm.
8. The lyophilized composition of claim 1 , wherein said nanoparticle complexes have an average size between about 130 nm and about 800 nm.
9. The lyophilized composition of claim 1 , wherein the ratio of albumin-paclitaxel nanoparticle to antibodies is between 10:1 and 10:30.
10. The lyophilized composition of claim 1 , wherein the ratio of albumin-paclitaxel nanoparticle to antibodies is between 10:2 and 10:6.
11. The lyophilized composition of claim 1 , wherein the antibodies are cetuximab or panitumumab.
12. The lyophilized composition of claim 11 , wherein the antibodies are cetuximab.
13. The lyophilized composition of claim 11 , wherein the antibodies are panitumumab.
14. The lyophilized composition of claim 11 , wherein less than 0.01% of nanoparticle complexes have a size greater than 800 nm.
15. The lyophilized composition of claim 11 , wherein said nanoparticle complexes have an average size between about 130 nm and about 800 nm.
16. The lyophilized composition of claim 11 , wherein the ratio of albumin-paclitaxel nanoparticle to antibodies is between 10:1 and 10:30.
17. The lyophilized composition of claim 11 , wherein the ratio of albumin-paclitaxel nanoparticle to antibodies is between 10:2 and 10:6.
18. The lyophilized composition of claim 1 , wherein each of the nanoparticle complexes comprises between about 100 and about 1000 antibodies.
19. The lyophilized composition of claim 1 , further comprising at least one additional cancer therapeutic agent.
20. The lyophilized composition of claim 1 , wherein the paclitaxel is associated with the albumin through non-covalent bonds.
21. The lyophilized composition of claim 11 , wherein the paclitaxel is associated with the albumin through non-covalent bonds.